Suppression of GPR56 mRNA expression in EVI1high AML cells by treatment of PIPs (PIP/56-1 and PIP/56-2) targeting EVI1-binding sequences of the GPR56 promoter region. Here, RUNX1 is linked to acute myeloid leukemia.